Hoth Therapeutics, Inc. (HOTH) Stock Analysis & Investment Frameworks
Hoth Therapeutics, Inc. (HOTH) stock analysis on Invetso. Review Hoth Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Hoth Therapeutics, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Hoth Therapeutics, Inc. Key Financial Metrics
- Market Cap: $10.62M
- Revenue: $N/A
- ROE: -199.23%
- ROIC: -160.57%
- Dividend Yield: N/A
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Hoth Therapeutics, Inc. Investment Frameworks
Invetso analyzes Hoth Therapeutics, Inc. (HOTH) across the following frameworks:
- Hoth Therapeutics, Inc. 10Y Growth Potential
- Hoth Therapeutics, Inc. Scenario Analysis
- Hoth Therapeutics, Inc. Risks & Opportunities
- Hoth Therapeutics, Inc. Economic Moat
- Hoth Therapeutics, Inc. Business Model
- Hoth Therapeutics, Inc. Management
- Hoth Therapeutics, Inc. SWOT Analysis
- Hoth Therapeutics, Inc. Porter's 5 Forces
- Hoth Therapeutics, Inc. PESTLE Analysis
- Hoth Therapeutics, Inc. ESG Analysis